Free Trial
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

NewAmsterdam Pharma logo
$20.92 -0.10 (-0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$20.92 0.00 (0.00%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

Key Stats

Today's Range
$20.88
$21.61
50-Day Range
$17.01
$22.17
52-Week Range
$14.06
$27.29
Volume
366,547 shs
Average Volume
738,786 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.89
Consensus Rating
Buy

Company Overview

NewAmsterdam Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

NAMS MarketRank™: 

NewAmsterdam Pharma scored higher than 55% of companies evaluated by MarketBeat, and ranked 511th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NewAmsterdam Pharma has only been the subject of 4 research reports in the past 90 days.

  • Read more about NewAmsterdam Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NewAmsterdam Pharma is -11.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NewAmsterdam Pharma is -11.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NewAmsterdam Pharma has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about NewAmsterdam Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    11.06% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in NewAmsterdam Pharma has recently decreased by 1.29%, indicating that investor sentiment is improving.
  • Dividend Yield

    NewAmsterdam Pharma does not currently pay a dividend.

  • Dividend Growth

    NewAmsterdam Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.06% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in NewAmsterdam Pharma has recently decreased by 1.29%, indicating that investor sentiment is improving.
  • News Sentiment

    NewAmsterdam Pharma has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for NewAmsterdam Pharma this week, compared to 6 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NewAmsterdam Pharma insiders have sold 714.48% more of their company's stock than they have bought. Specifically, they have bought $236,839.00 in company stock and sold $1,929,000.00 in company stock.

  • Percentage Held by Insiders

    20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NewAmsterdam Pharma's insider trading history.
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

NAMS Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
NewAmsterdam Pharma Company N.V. (NAMS) - Yahoo Finance
See More Headlines

NAMS Stock Analysis - Frequently Asked Questions

NewAmsterdam Pharma's stock was trading at $25.70 at the start of the year. Since then, NAMS shares have decreased by 18.6% and is now trading at $20.92.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.04. The business had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. NewAmsterdam Pharma had a negative trailing twelve-month return on equity of 37.34% and a negative net margin of 397.45%.

Top institutional shareholders of NewAmsterdam Pharma include Atle Fund Management AB (0.14%), PTM Wealth Management LLC (0.01%) and Avanza Fonder AB (0.01%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Douglas F Kling, Louis G Lange, Louise Frederika Kooij, Juliette Berangere Audet and Johannes Jacob Piete Kastelein.
View institutional ownership trends
.

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

Last Earnings
5/08/2025
Today
7/16/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NAMS
CIK
1936258
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$52.00
Low Price Target
$37.00
Potential Upside/Downside
+104.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$241.60 million
Net Margins
-397.45%
Pretax Margin
-397.45%
Return on Equity
-37.34%
Return on Assets
-33.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.98
Quick Ratio
19.98

Sales & Book Value

Annual Sales
$45.56 million
Price / Sales
51.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.20 per share
Price / Book
2.56

Miscellaneous

Outstanding Shares
112,270,000
Free Float
88,874,000
Market Cap
$2.36 billion
Optionable
Optionable
Beta
-0.03
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:NAMS) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners